{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:51:02Z","timestamp":1770432662082,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.3816\/ccc.2006.n.007","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:06:15Z","timestamp":1221080775000},"page":"359-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Is Capecitabine Safe in Patients with Gastrointestinal Cancer and Dihydropyrimidine Dehydrogenase Deficiency?"],"prefix":"10.3816","volume":"5","author":[{"given":"M. Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Diasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2006.n.007_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","article-title":"Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity","volume":"696","author":"Johnson","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.3816\/CCC.2006.n.007_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients","volume":"45","author":"Sch\u00fcller","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2006.n.007_bib3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2125.1979.tb04651.x","article-title":"Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients","volume":"7","author":"Finch","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"10.3816\/CCC.2006.n.007_bib4","first-page":"2117","article-title":"Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-flourouracil in colorectal cancer","volume":"45","author":"Nita","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"10.3816\/CCC.2006.n.007_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000028401","article-title":"The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil","volume":"61","author":"Diasio","year":"2000","journal-title":"Pharmacology"},{"key":"10.3816\/CCC.2006.n.007_bib6","first-page":"197","article-title":"Relationship between didyropyrimidine dedydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion","volume":"50","author":"Harris","year":"1990","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2006.n.007_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","article-title":"Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil","volume":"41","author":"Johnson","year":"2001","journal-title":"Adv Enzyme Regul"},{"key":"10.3816\/CCC.2006.n.007_bib8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14622416.3.4.485","article-title":"Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics","volume":"3","author":"Mattison","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.3816\/CCC.2006.n.007_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","article-title":"Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome","volume":"68","author":"Harris","year":"1991","journal-title":"Cancer (Phila)"},{"key":"10.3816\/CCC.2006.n.007_bib10","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.007_bib11","first-page":"325","article-title":"Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy","volume":"4","author":"Lu","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.007_bib12","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Results of a large phase III study","volume":"19","author":"Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.007_bib13","first-page":"338","article-title":"Up-regulation of thymidine phosphorylase (TP) by radiotherapy (RT): a phase I study of capecitabine (CAP) with concurrent RT for pts with locally advanced (LA) pancreatic cancer (Pan Ca)","volume":"23","author":"Saif","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2006.n.007_bib14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/cncr.20368","article-title":"Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma","volume":"101","author":"Patt","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CCC.2006.n.007_bib15","first-page":"551","article-title":"Dihydropyrimidine dehydrogenase, multi drug resistance associated with protein and thymidylate synthase gene expression levels can predict 5-flourouracil resistance in human gastrointestinal cancer cells","volume":"14","author":"Kirihara","year":"1999","journal-title":"Int J Oncol"},{"key":"10.3816\/CCC.2006.n.007_bib16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.bjc.6600040","article-title":"Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer","volume":"86","author":"Horiguchi","year":"2002","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2006.n.007_bib17","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"pt 2","key":"10.3816\/CCC.2006.n.007_bib18","first-page":"140b","article-title":"Tolerance of capecitabine in a patient with partial dihyrdopyrimidine dehydrogenase (DPD) deficiency who experienced life threatening toxicity to 5FU","volume":"21","author":"Mininberg","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2006.n.007_bib19","author":"Muss"},{"key":"10.3816\/CCC.2006.n.007_bib20","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2002.10.129","article-title":"Randomized comparative study of tegafur\/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer","volume":"20","author":"Carmichael","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.007_bib21","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2002.04.123","article-title":"Multicenter phase III study of uracil\/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer","volume":"20","author":"Douillard","year":"2002","journal-title":"J Clin Oncol"},{"issue":"pt 1","key":"10.3816\/CCC.2006.n.007_bib22","first-page":"132a","article-title":"North American phase III study of oral eniluracil (EU) plus oral 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC)","volume":"20","author":"Levin","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2006.n.007_bib23","first-page":"31","article-title":"Effect of celecoxib on capecitabineinduced hand-foot syndrome and antitumor activity","volume":"16","author":"Lin","year":"2002","journal-title":"Oncology (Huntingt)"},{"key":"10.3816\/CCC.2006.n.007_bib24","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","article-title":"Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test","volume":"10","author":"Mattison","year":"2004","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811702092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811702092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:58:47Z","timestamp":1761519527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811702092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S1533002811702092"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2006.n.007","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is Capecitabine Safe in Patients with Gastrointestinal Cancer and Dihydropyrimidine Dehydrogenase Deficiency?","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2006.n.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}